Novel emerging biomarkers to immunotherapy in kidney cancer

por Ged, Yasser, Voss, Martin H.
Publicado 2021

Prognostic models in papillary renal cell carcinoma

por Attalla, Kyrollis, Voss, Martin H., Hakimi, A. Ari
Publicado 2020

In silico modeling of combination systemic therapy for advanced renal cell carcinoma

por Kotecha, Ritesh R, Hsu, Dennis J, Lee, Chung-Han, Patil, Sujata, Voss, Martin H
Publicado 2021

Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events

por Grünwald, Viktor, Voss, Martin H., Rini, Brian I., Powles, Thomas, Albiges, Laurence, Giles, Rachel H., Jonasch, Eric
Publicado 2020

Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma

por Voss, Martin H, Chen, David, Marker, Mahtab, Hakimi, A Ari, Lee, Chung-Han, Hsieh, James J, Knox, Jennifer J, Voi, Maurizio, Motzer, Robert J
Publicado 2016

Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy

por Lattanzi, Michael, Deng, Fang-Ming, Chiriboga, Luis A., Femia, Alisa N., Meehan, Shane A., Iyer, Gopa, Voss, Martin H., Sundatova, Yuliya, Huang, William C., Balar, Arjun V.
Publicado 2018

Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic

por Sarfaty, Michal, Feldman, Darren R., Morris, Michael J., Motzer, Robert J., Rathkopf, Dana E., Regazzi, Ashley M., Iyer, Gopa, Voss, Martin H., Bajorin, Dean F., Rosenberg, Jonathan E.
Publicado 2021

Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma

por Lee, Chung-Han, Motzer, Robert J., Glen, Hilary, Michaelson, M. D., Larkin, James, Minoshima, Yukinori, Kanekiyo, Michio, Ikezawa, Hiroki, Sachdev, Pallavi, Dutcus, Corina E., Funahashi, Yasuhiro, Voss, Martin H.
Publicado 2020

Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma

por Abida, Wassim, Milowsky, Matthew I., Ostrovnaya, Irina, Gerst, Scott R., Rosenberg, Jonathan E., Voss, Martin H., Apolo, Andrea B., Regazzi, Ashley M., McCoy, Asia S., Boyd, Mariel E., Bajorin, Dean F.
Publicado 2016

Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations

por Ged, Yasser, Gupta, Ruby, Duzgol, Cihan, Knezevic, Andrea, Shapnik, Natalie, Kotecha, Ritesh, Voss, Martin H., Feldman, Darren R., Akin, Oguz, Patil, Sujata, Motzer, Robert J., Rini, Brian I., Lee, Chung-Han
Publicado 2020

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade

por Beattie, Jason, Rizvi, Hira, Fuentes, Paige, Luo, Jia, Schoenfeld, Adam, Lin, I-Hsin, Postow, Michael, Callahan, Margaret, Voss, Martin H, Shah, Neil J, Betof Warner, Allison, Chawla, Mohit, Hellmann, Matthew D
Publicado 2021

A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

por Voss, Martin H., Azad, Arun A., Hansen, Aaron R., Gray, Jhanelle E., Welsh, Sarah J., Song, Xuyang, Kuziora, Michael, Meinecke, Lina, Blando, Jorge, Achour, Ikbel, Wang, Yi, Walcott, Farzana L., Oosting, Sjoukje F.
Publicado 2022

A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors

por Harding, James J., Telli, Melinda, Munster, Pamela, Voss, Martin H., Infante, Jeffrey R., DeMichele, Angela, Dunphy, Mark, Le, Mai H., Molineaux, Chris, Orford, Keith, Parlati, Frank, Whiting, Sam H., Bennett, Mark K., Tannir, Nizar M., Meric-Bernstam, Funda
Publicado 2021

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

por Amin, Asim, Plimack, Elizabeth R, Ernstoff, Marc S, Lewis, Lionel D, Bauer, Todd M, McDermott, David F, Carducci, Michael, Kollmannsberger, Christian, Rini, Brian I, Heng, Daniel Y C, Knox, Jennifer, Voss, Martin H, Spratlin, Jennifer, Berghorn, Elmer, Yang, Lingfeng, Hammers, Hans J
Publicado 2018

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

por Amin, Asim, Plimack, Elizabeth R., Ernstoff, Marc S., Lewis, Lionel D., Bauer, Todd M., McDermott, David F., Carducci, Michael, Kollmannsberger, Christian, Rini, Brian I., Heng, Daniel Y. C., Knox, Jennifer, Voss, Martin H., Spratlin, Jennifer, Berghorn, Elmer, Yang, Lingfeng, Hammers, Hans J.
Publicado 2019

DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy

por Ged, Yasser, Chaim, Joshua L, DiNatale, Renzo G, Knezevic, Andrea, Kotecha, Ritesh R, Carlo, Maria I, Lee, Chung-Han, Foster, Ashley, Feldman, Darren R, Teo, Min Yuen, Iyer, Gopakumar, Chan, Timothy, Patil, Sujata, Motzer, Robert J, Hakimi, A Ari, Voss, Martin H
Publicado 2020

A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response

por Hakimi, A. Ari, Attalla, Kyrollis, DiNatale, Renzo G., Ostrovnaya, Irina, Flynn, Jessica, Blum, Kyle A., Ged, Yasser, Hoen, Douglas, Kendall, Sviatoslav M., Reznik, Ed, Bowman, Anita, Hwee, Jason, Fong, Christopher J., Kuo, Fengshen, Voss, Martin H., Chan, Timothy A., Motzer, Robert J.
Publicado 2020

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

por Voss, Martin H., Gordon, Michael S., Mita, Monica, Rini, Brian, Makker, Vicky, Macarulla, Teresa, Smith, David C., Cervantes, Andrés, Puzanov, Igor, Pili, Roberto, Wang, Ding, Jalal, Shadia, Pant, Shubham, Patel, Manish R., Neuwirth, Rachel l., Enke, Aaron, Shou, Yaping, Sedarati, Farhad, Faller, Douglas V., Burris, Howard A.
Publicado 2020

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

por Rini, Brian I., Battle, Dena, Figlin, Robert A., George, Daniel J., Hammers, Hans, Hutson, Tom, Jonasch, Eric, Joseph, Richard W., McDermott, David F., Motzer, Robert J., Pal, Sumanta K., Pantuck, Allan J., Quinn, David I., Seery, Virginia, Voss, Martin H., Wood, Christopher G., Wood, Laura S., Atkins, Michael B.
Publicado 2019

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase...

por Bilen, Mehmet A., Rini, Brian I., Voss, Martin H., Larkin, James, Haanen, John B.A.G., Albiges, Laurence, Pagliaro, Lance C., Voog, Eric G., Lam, Elaine T., Kislov, Nikolay, McGregor, Bradley A., Lalani, Aly-Khan A., Huang, Bo, di Pietro, Alessandra, Krulewicz, Stan, Robbins, Paul B., Choueiri, Toni K.
Publicado 2022